Clinical Report: Intraperitoneal Chemotherapy via Catheter with Taxanes

Overview

This narrative review discusses the application of intraperitoneal chemotherapy using taxanes for treating peritoneal metastases in gastric cancer. It highlights the unique challenges posed by peritoneal metastasis and the application of catheter-based delivery methods.

Background

Gastric cancer is a significant global health issue, with a high incidence of peritoneal metastasis, particularly in advanced stages. Standard systemic chemotherapy often proves ineffective due to the distinct biological characteristics of peritoneal metastasis, leading to poor survival rates. Therefore, alternative treatment strategies, such as intraperitoneal chemotherapy, are explored.

Data Highlights

No specific numerical data or trial results were provided in the source material, which limits the review's conclusions.

Key Findings

• Peritoneal metastasis occurs in approximately 40-50% of patients with stage IV gastric cancer.
• Median survival for patients with peritoneal metastasis receiving systemic chemotherapy ranges from 4 to 12 months.
• Intraperitoneal chemotherapy allows for direct delivery of high concentrations of cytotoxic agents into the peritoneal cavity.
• Catheter-based normothermic intraperitoneal chemotherapy (CBIP) has been adapted for gastric cancer treatment in Japan and other Asian countries.
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has shown promising results in early studies for gastric cancer with peritoneal metastasis.

Clinical Implications

The review emphasizes the need for innovative approaches to enhance drug delivery in gastric cancer with peritoneal metastasis.

Conclusion

Intraperitoneal chemotherapy via catheter represents a strategy for managing peritoneal metastases in gastric cancer.

Related Resources & Content

1. The ASCO Post, 2017 -- Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases Novel Therapy for Stage IV Gastric Cancer Related Articles
2. Journal of Gastrointestinal Surgery, 2015 -- Low-Dose Cisplatin and Doxorubicin Administered via Pressurized Intraperitoneal Aerosol Chemotherapy for Gastric Peritoneal Metastases
3. The ASCO Post, 2015 -- What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?
4. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
5. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial | Trials | JAMA Oncology
6. Combination of Intraperitoneal Paclitaxel with FOLFOX/CAPOX and Bevacizumab for Colorectal Cancer with Peritoneal Carcinomatosis: Protocol for the iPac-02 Phase 2 Multicenter Study
7. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
8. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial | Trials | JAMA Oncology | JAMA Network
9. Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis - PMC